References
- Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–341; quiz 42–44.
- Tanghetti EA, Jackson JM, Belasco KT, Friedrichs A, Hougier F, Johnson SM, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14(1):33–40.
- Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015;8:159–177.
- Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633–641.
- Dahan S. Laser and intense pulsed light management of couperose and rosacea. Ann Dermatol Venereol. 2011;138(Suppl. 3):S219–S222.
- Mazer JM. Role of laser in the treatment of rosacea. Ann Dermatol Venereol. 2014;141(Suppl. 2):S175–S178.
- Mansouri Y, Goldenberg G. Devices and topical agents for rosacea management. Cutis. 2014;94(1):21–25.
- Uebelhoer NS, Bogle MA, Stewart B, Arndt KA, Dover JS. A split-face comparison study of pulsed 532-nm KTP laser and 595-nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema. Dermatol Surg. 2007;33(4):441–448.
- Uebelhoer NS, Bogle MA, Stewart B, Arndt KA, Dover JS. A split-face comparison study of pulsed 532-nm KTP laser and 595-nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema. Dermatol Surg. 2007;33(4):441–448.
- European Medicines Agency. SOOLANTRA® – Summary of product characteristics; April 2015.